Immune response
Gene:
IGF2BP3 (official gene symbol)Other symbol:
IMP-3CT family:
CT98CT identifier:
CT98Humoral immune response
Spontaneous humoral immune responses against IMP-3 have been detected in cancer patients.
| Tumor type | Tumor stage | Frequency | Antibody detection methodology | PMID |
|---|---|---|---|---|
| Breast carcinoma | 12/98 (12%) | ELISA | 11465943 | |
| Colorectal carcinoma | 9/65 (14%) | ELISA | 11465943 | |
| Esophageal carcinoma | 15/119 (13%) | ELISA | 11465943 | |
| Hepatocellular carcinoma | 13/75 (17%) | ELISA | 11465943 | |
| Gastrict carcinoma | 22/135 (16%) | ELISA | 11465943 | |
| Lung carcinoma | 6/84% (7%) | ELISA | 11465943 | |
| Lymphoma | 8/72 (11%) | ELISA | 11465943 | |
| Pharyngeal carcinoma | 6/56 (11%) | ELISA | 11465943 | |
| Ovarian cancer | 1/33 (3%) | ELISA | 11465943 | |
| Uterine carcinoma | 3/40 (7%) | ELISA | 11465943 | |
| Lung carcinoma | Pleural effusion | 8/17 (47%) | ELISA | 12644826 |
Cellular immune response
IMP-3 (KOC) was identified by serological screening of cDNA expression library from SK-MEL-37 melanoma cell line (Chen et al., 1998 PMID: 9618514).
IMP-3 protein is recognized by CTLs and a HLA-A24-restricted epitope can induce potent and specific immune responses against lung and esophageal cancer cells (Suda et al., 2007 PMID: 17784873).Specific T-cell responses to epitope peptides derived from IMP-3 are induced in TIL, RLNL, and PBL from HLA-A2402 patients with esophageal squamous cell carcinoma Mizukami et al., 2008 PMID: 18452554).